# Female Urethral Adenocarcinoma Posing a Diagnostic Challenge

**Authors:** Omar Darboe, Bartholomeo Nicholaus Ngowi, Gideon Mwasakyalo, Christine Mwakio, Rosemary Wangari Kamau, Adan S. Bashir, Waithera David, Paul Juma Irungu

PMC · DOI: 10.1002/ccr3.70716 · Clinical Case Reports · 2025-07-30

## TL;DR

This paper presents a case of a rare female urethral cancer that was diagnosed after a long period of symptoms and highlights the importance of a multidisciplinary approach for effective treatment.

## Contribution

The paper contributes a detailed case study of female urethral adenocarcinoma with a focus on diagnostic and treatment challenges.

## Key findings

- A 53-year-old woman was diagnosed with well-differentiated urethral adenocarcinoma after a 9-month history of urinary symptoms.
- Chemoradiotherapy was effective in treating the cancer, with no recurrence observed during follow-up.
- Multidisciplinary team involvement is crucial for managing this rare and challenging cancer.

## Abstract

Generally, urethral malignancies are uncommon urological tumors that are more frequent in women than in men. The etiology of female urethral adenocarcinoma is yet unknown. Recurrent UTIs and urethral diverticula are two common risk factors linked to it. Clinical presentations can differ and are not always specific. A complete history and physical examination are part of management; urethrocystoscopy with urethral biopsy is used for diagnosis; investigations such as magnetic resonance imaging or abdominal computed tomography scans are used for staging; and treatment options include monotherapy and multimodal therapy. A 53‐year‐old female who presented with a 9‐month history of lower urinary tract symptoms characterized by a burning sensation when passing urine, increased urinary frequency, and a feeling of incomplete bladder emptying associated with a feeling of a vaginal mass. A fixed fungating mass at the external urethral orifice was seen. Pelvic magnetic resonance imaging reported a retropubic urethral mass with bilateral inguinal lymph nodes. She underwent urethrocystoscopy with multiple urethral biopsies taken, and the specimen was sent for histopathology, which confirmed a well‐differentiated urethral adenocarcinoma with mucin production. She was treated with chemoradiotherapy as per multidisciplinary team (MDT) meeting recommendations. She developed symptoms of radiation proctitis, which were treated with argon plasma coagulation. She has since been on follow‐up at our oncology clinic, and a subsequent positron emission tomography CT scan reported no tumor recurrence or metastasis. She is currently doing well with no recurrence of symptoms. Although female urethral adenocarcinoma is uncommon, it requires comprehensive investigation when it is suspected, particularly in women who have nonspecific or recurrent lower urinary tract symptoms. Management should involve a MDT approach where available. Depending on the disease's stage and location, treatment options may include surgery, nonsurgical options such as radiotherapy and chemotherapy, or a combination. Patients should be monitored for any signs of recurrence of the illness. A better prognosis is said to exist for distal urethral cancers that are localized.

## Linked entities

- **Diseases:** urethral adenocarcinoma (MONDO:0003200), radiation proctitis (MONDO:0019084)

## Full-text entities

- **Genes:** TENM1 (teneurin transmembrane protein 1) [NCBI Gene 10178] {aka ODZ1, ODZ3, TEN-M1, TEN1, TNM, TNM1}, NPEPPS (aminopeptidase puromycin sensitive) [NCBI Gene 9520] {aka AAP-S, MP100, PSA}, mucin [NCBI Gene 100508689]
- **Diseases:** fistula (MESH:D005402), skin lesions (MESH:D012871), lymphoma (MESH:D008223), Female urethral adenocarcinoma (MESH:D000230), urological malignancy (MESH:D014571), Tumor (MESH:D009369), urethral obstruction (MESH:D014524), smoker (MESH:C000719328), disorder (MESH:D009358), genitourinary tract tumors (MESH:C564424), fibroids (MESH:D007889), vulvar or vaginal melanoma (MESH:D008545), urethral (MESH:D014526), pain (MESH:D010146), abscess (MESH:D000038), sexually transmitted diseases (MESH:D012749), tenderness (MESH:D063806), polyps (MESH:D011127), viral infections (MESH:D014777), radiation proctitis (MESH:D011349), transitional cell carcinomas (MESH:D002295), metastasis (MESH:D009362), chronic irritation (MESH:D002908), bleeding (MESH:D006470), urethral mass (MESH:D014522), desquamation (MESH:D017490), distal urethral cancers (MESH:D014523), dysuria (MESH:D053159), genitourinary tumors (MESH:D014565), Neuroendocrine tumors (MESH:D018358), dyspareunia (MESH:D004414), urinary tract infection (MESH:D014552), leukoplakia (MESH:D007971), urethral diverticular (MESH:D000076385), urinary tract symptoms (MESH:D014570), lymphadenopathy (MESH:D008206), squamous cell carcinoma (MESH:D002294), human papilloma virus infection (MESH:D010212), hematuria (MESH:D006417)
- **Chemicals:** urea (MESH:D014508), creatinine (MESH:D003404), argon (MESH:D001128)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12311218/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12311218/full.md

## References

19 references — full list in the complete paper: https://tomesphere.com/paper/PMC12311218/full.md

---
Source: https://tomesphere.com/paper/PMC12311218